| Literature DB >> 35577077 |
A N Kazantsev1, M R Karkayeva2, A P Tritenko3, A V Korotkikh4, A S Zharova3, K P Chernykh5, G Sh Bagdavadze3, R Yu Lider6, Ye G Kazantseva6, K L Zakharova5, D V Shmatov7, V N Kravchuk3, K S Peshekhonov5, N E Zarkua3, V A Lutsenko8, R V Sultanov8, S V Artyukhov5, E U Kharchilava3, K N Solotenkova3, A B Zakeryayev9.
Abstract
Analysis of the results of emergency carotid endarterectomy (CEE) against the background of internal carotid artery (ICA) thrombosis in the acute period of acute cerebrovascular accident (ACVA) in patients with COVID-19. During the COVID-19 pandemic (April 1, 2020-May 1, 2021), 43 patients with ICA thrombosis and a positive polymerase chain reaction (PCR) result for SARS-CoV-2 were included in this prospective study. In all cases, CEE was performed in the acutest period of ACVA. These patients were included in group 1. The comparison group was represented by 89 patients who underwent CEE in the acute period of stroke, in the period before the COVID-19 pandemic (April 1, 2019-March 1, 2020). According to laboratory parameters, patients with COVID-19 had severe coagulopathy (with an increase in D-dimer: 3832 ± 627.2 ng/mL, fibrinogen: 12.6 ± 3.1 g/L, prothrombin: 155.7 ± 10, 2%), inflammatory syndrome (increased ferritin: 646.2 ± 56.1 ng/mL, C-reactive protein: 161.3 ± 17.2 mg/L, interleukin-6: 183.3 ± 51.7 pg/mL, leukocytosis: 27.3 ± 1.7 10E9/L). In the hospital postoperative period, the groups were comparable in terms of the incidence of deaths (group 1: 2.3%, n = 1; group 2: 1.1%, n = 1; P= 0.81; OR=2.09; 95 % CI = 0.12-34.3) myocardial infarction (group 1: 2.3%, n = 1; group 2: 0%; P= 0.7; OR = 6.3; 95% CI = 0.25-158.5), CVA (group 1: 2.3%, n = 1; group 2: 2.2%, n = 2; P= 0.55; OR = 1.03; 95% CI = 0,.09-11.7). ICA thrombosis and hemorrhagic transformations were not recorded. However, due to severe coagulopathy with ongoing anticoagulant/antiplatelet therapy, patients with COVID-19 more often developed bleeding in the operation area (group 1: 11.6%, n = 5; group 2: 1.1%, n = 1; P= 0.02; OR = 11.5; 95% CI = 1.3-102.5). In all cases, the flow of hemorrhagic discharge came from the drainage localized in the subcutaneous fat. This made it possible to remove skin sutures in a dressing room, suturing the source of bleeding and applying secondary sutures under local anesthesia. Emergency CEE in the acute period of stroke is an effective and safe method of cerebral revascularization in case of ICA thrombosis in conditions of COVID-19.Entities:
Year: 2022 PMID: 35577077 PMCID: PMC9109971 DOI: 10.1016/j.cpcardiol.2022.101252
Source DB: PubMed Journal: Curr Probl Cardiol ISSN: 0146-2806 Impact factor: 16.464
Comparative clinical and anamnestic characteristic of patient groups
| Indicator | Group 1(with COVID-19) | Group 2(without COVID-19) | OR | 95% Confidence interval | |
|---|---|---|---|---|---|
| Age, М ± m, y | 64.2 ± 5.3 | 65.7 ± 3.9 | 0.32 | - | - |
| Male sex, | 31 (72.1) | 67 (75.3) | 0.85 | 0.84 | 0.37-1.93 |
| Postinfarction cardiosclerosis, | 6 (13.9) | 15 (16.8) | 0.86 | 0.8 | 0.28-2.23 |
| Diabetes mellitus, | 3 (6.9) | 6 (6.7) | 0.75 | 1.03 | 0.24-4.36 |
| Chronic obstructive pulmonary disease, | 13 (30.2) | 1 (1.1) | <0.0001 | 38.1 | 4.78-304.1 |
| Chronic renal failure, | 3 (6.9) | 1 (1.1) | 0.19 | 6.6 | 0.66-65.4 |
| Left ventricular ejection fraction, М ± m, % | 60.5 ± 2.5 | 61.8 ± 2.7 | 0.45 | - | - |
| Left ventricular aneurysm, | 0 | 1 (1.1) | 0.7 | 0.67 | 0.02-17.01 |
| History of percutaneous coronary intervention, | 5 (11.6) | 10 (11.2) | 0.82 | 1.03 | 0.33-3.25 |
| History of coronary artery bypass surgery, | 3 (6.9) | 6 (6.7) | 0.75 | 1.03 | 0.24-4.36 |
| Recurrent acute cerebrovascular accident, | 11 (25.6) | 23 (25.8) | 0.85 | 0.98 | 0.42-2.27 |
| Lung tissue damage, М ± m, % | 65.2 ± 13.5 | - | - | - | - |
| SpO2, М ± m, % | 87.5 ± 4.8 | 98.0 ± 1.0 | 0.001 | - | - |
Laboratory indicators
| Indicator | Group 1(with COVID-19) | Group 2(without COVID-19) | |
|---|---|---|---|
| Leukocytes, М ± m, 10Е9/л | 27.3 ± 1.7 | 5.1 ± 0.6 | 0.001 |
| Ferritin, М ± m, нг/мл | 646.2 ± 56.1 | - | - |
| C-reactive protein, М ± m, мг/л | 161.3 ± 17.2 | 2.5 ± 0.5 | 0.003 |
| Interleukin 6, М ± m, пг/мл | 183.3 ± 51,7 | - | - |
| D-dimer, М ± m, нг/мл | 3832 ± 627.2 | - | - |
| Fibrinogen, М ± m, гр/л | 12.6 ± 3.1 | 2.8 ± 0.4 | 0.01 |
| Prothrombin, М ± m, % | 155.7 ± 10.2 | 93.4 ± 6.9 | 0.004 |
Angiographic and perioperative characteristics
| Indicator | Group 1(with COVID-19) | Group 2(without COVID-19) | |
|---|---|---|---|
| % stenosis of the internal carotid artery | 78.4 ± 5.3 | 79.1 ± 6.1 | 0.34 |
| Clamping time of the internal carotid artery, min | 22.5 ± 1.7 | 21.4 ± 2.4 | 0.51 |
Hospital outcomes
| Indicator | Group 1 (with COVID-19) | Group 2 (without COVID-19) | OR | 95% Confidence interval | |
|---|---|---|---|---|---|
| Death, | 1 (2.3) | 1 (1.1) | 0.81 | 2.09 | 0.12-34.3 |
| Myocardial infarction, | 1 (2.3) | 0 | 0.7 | 6.3 | 0.25-158.5 |
| Ischemic stroke, | 1 (2.3) | 2 (2.2) | 0.55 | 1.03 | 0.09-11.7 |
| Hemorrhagic transformation, | 0 | 0 | - | - | - |
| Bleeding, | 5 (11.6) | 1 (1.1) | 0.02 | 11.5 | 1.3-102.5 |
| Thrombosis of the internal carotid artery, | 0 | 0 | - | - | - |
| Combined Endpoint, | 4 (6.9) | 3 (3.4) | 0.31 | 2.94 | 0.62-13.78 |